Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Table 3 Summary of progression-free survival
| Group A (n = 20) | Group C (n = 14) | |
| Patients with event | 11 (55.0%) | 4 (28.6%) |
| Patients without event | 9 (45.0%) | 10 (71.4%) |
| Time to event (mo) | ||
| Median | 17 | - |
| 95%CI | 8.0, - | 9.0, - |
| 25% and 75%-ile | 8.50, - | 12.0, - |
| Min-max | 5-26 | 0.5-35 |
| 12 mo probability (95%CI) | 55.0 (31.3-73.5) | 67.7 (34.9-86.5) |
| 18 mo probability (95%CI) | 50.0 (27.1-69.2) | 67.7 (34.9-86.5) |
- Citation: Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5641